Canada markets open in 4 hours 4 minutes
  • S&P/TSX

    20,365.85
    +78.05 (+0.38%)
     
  • S&P 500

    4,423.15
    +35.99 (+0.82%)
     
  • DOW

    35,116.40
    +278.24 (+0.80%)
     
  • CAD/USD

    0.7975
    -0.0006 (-0.07%)
     
  • CRUDE OIL

    70.42
    -0.14 (-0.20%)
     
  • BTC-CAD

    47,405.09
    -1,110.50 (-2.29%)
     
  • CMC Crypto 200

    923.86
    -19.58 (-2.07%)
     
  • GOLD FUTURES

    1,814.50
    +0.40 (+0.02%)
     
  • RUSSELL 2000

    2,223.58
    +8.09 (+0.36%)
     
  • 10-Yr Bond

    1.1760
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,051.00
    +4.75 (+0.03%)
     
  • VOLATILITY

    18.23
    -1.23 (-6.32%)
     
  • FTSE

    7,127.87
    +22.15 (+0.31%)
     
  • NIKKEI 225

    27,584.08
    -57.75 (-0.21%)
     
  • CAD/EUR

    0.6725
    +0.0003 (+0.04%)
     

Frequency Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

·2 min read

Investors with losses are encouraged to contact the firm before August 2, 2021; click here to submit trade information

LOS ANGELES, June 15, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Frequency Therapeutics, Inc. (NASDAQ: FREQ) investors that acquired shares between November 16, 2020 and March 22, 2021. Investors have until July 13, 2021 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

Frequency Therapeutics has conducted several clinical studies evaluating the safety and effectiveness of FX-322, the most significant of which was a Phase 2a study, beginning in October 2019. In April 2020, David L. Lucchino Frequency’s Chief Executive Officer (“CEO”), began selling his shares of Frequency, totaling over 350,000 shares sold, earning over $10.5 million.

Before the market opened, on March 23, 2021, Frequency disclosed in a press release disappointing interim results of the Phase 2a study, which revealed that subjects with mild to moderate SNHL did not demonstrate improvements in hearing measures versus placebo.

Frequency’s shares fell $28.30, or 78%, on this news, to close at $7.99 per share, thereby damaging investors.

It is alleged in this complaint that throughout the Class Period, Frequency made materially misleading and/or false statements, as well as failed to disclose material adverse facts about Frequency’s business, operations, and prospects. Specifically, Frequency failed to disclose: (1) that Frequency’s Phase 2a study did not yield positive results in support of commercialization of FX-322; and (2) that, as a result, Frequency’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 2, 2021.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting